Several studies have evaluated glucose-related therapies as strategies to improve outcome in acute coronary syndromes, such as high dose glucose-insulin-potassium (GIK) infusion [11,12], or combined glucose-insulin infusion to reduce glucose levels [13,14]. This evidence concerns the gene INS and acute coronary syndrome.